Equities

Niox Group PLC

NIOX:LSE

Niox Group PLC

Health CareMedical Equipment and Services
  • Price (GBX)73.80
  • Today's Change0.60 / 0.82%
  • Shares traded231.04k
  • 1 Year change27.24%
  • Beta1.3244
Data delayed at least 20 minutes, as of May 20 2024 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.

  • Revenue in GBP (TTM)36.80m
  • Net income in GBP9.50m
  • Incorporated2006
  • Employees85.00
  • Location
    Niox Group PLCHayakawa BuildingThe Oxford Science ParkOXFORD OX4 4GBUnited KingdomGBR
  • Phone+44 18 6540 5560Fax+44 18 6578 4576
  • Websitehttps://investors.niox.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Avacta Group Plc16.03m-42.08m155.29m120.00155.29m120.00
Faron Pharmaceuticals Oy0.00-26.49m179.63m34.00179.63m34.00
4Basebio PLC354.00k-6.28m180.55m--180.55m--
hVIVO PLC56.04m16.12m187.10m274.00187.10m274.00
Alliance Pharma plc170.05m-7.06m191.30m249.00191.30m249.00
Bioventix PLC13.60m8.67m228.36m16.00228.36m16.00
Niox Group PLC36.80m9.50m310.40m85.00310.40m85.00
Oxford BioMedica plc89.54m-157.49m323.50m714.00323.50m714.00
Data as of May 20 2024. Currency figures normalised to Niox Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

38.47%Per cent of shares held by top holders
HolderShares% Held
Harwood Capital LLPas of 31 Dec 202377.76m18.39%
Lombard Odier Asset Management (Europe) Ltd.as of 07 Aug 202018.13m4.29%
Invesco Asset Management Ltd.as of 16 Jan 202015.66m3.70%
Danske Bank A/S (Investment Management)as of 27 Jan 202213.48m3.19%
Morgan Stanley Smith Barney LLC (Investment Management)as of 01 Feb 20249.71m2.30%
Merchant Capital Manager Ltd.as of 19 Aug 20208.67m2.05%
Schroder & Co Bank AG (Private Banking)as of 01 Feb 20245.99m1.42%
Brooks Macdonald Asset Management Ltd.as of 01 Feb 20244.81m1.14%
JPMorgan Asset Management (UK) Ltd.as of 01 Feb 20244.29m1.02%
Amiral Gestion SAas of 30 Jun 20234.13m0.98%
More ▼
Data from 31 Mar 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.